Consumer Alert: FDA Panel Urges Stronger Child and Adolescent Suicide Warnings on Antidepressants, including Paxil, Zoloft and Effexor
September 15, 2004
A panel of expert advisers recommended on September 15, 2004, to the FDA that antidepressants should come with the nation's strongest warning -- in a black box on the label -- that children and teenagers taking these drugs may be at an increased risk for suicidal behavior. The recommendation applies to all antidepressants, including Paxil, Zoloft and Effexor.
In addition, the panel recommended that antidepressants prescribed to minors should be accompanied by an easy-to-read pamphlet that explains how to decide if a child is a good patient for the drug, and lists the warning signs of suicide. The panel also urged the FDA to consider having parents sign a form indicating that they understand the risks before the child receives antidepressants. The panel's actions are based upon its review of scientific studies concerning the drugs. FDA predicts that it will act upon the recommendations– FDA usually follows the recommendations of its advisory panels– within a few months.
The drugs are approved by the FDA for use in adults, but there has not been a showing that Paxil, Zoloft or Effexor are effective in treating depression in children. Paxil is manufactured GlaxoSmithKline, Zoloft by Pfizer and Effexor by Wyeth.
There have been some legal cases involving antidepressants, including Paxil. If you have questions of a legal nature, please contact Tara Sutton.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.